✦ LIBER ✦

CA125 decline in ovarian cancer patients treated with intravenous versus intraperitoneal platinum-based chemotherapy

✍ Scribed by Debra L. Richardson; Leigh G. Seamon; Matthew J. Carlson; David M. O'Malley; Jeffrey M. Fowler; Larry J. Copeland; David E. Cohn

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

CA125 regression in ovarian cancer patie

✍ Ginger J. Gardner; Raymond E. Baser; Mark F. Brady; Robert E. Bristow; Maurie Ma 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 404 KB

Intraperitoneal therapy as consolidation

✍ Lu, M.Janice; Sorich, Joan; Hazarika, Maitreyee; Kim, Mimi; Del Priore, Giuseppe 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 96 KB

A Gynecologic Oncology Group Study of se

✍ Thomas C. Krivak; Chunqiao Tian; G. Scott Rose; Deborah K. Armstrong; G. Larry M 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 318 KB

Nadir CA125 and second look surgery in p

✍ S. Richard; A. Miller; M. Markman; D. Armstrong; J. Walker; T. Krivak 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 128 KB

517 Clinical (WHO) and serum tumor marke

✍ J.B. Vermorken; R.V.H.P. Huijskes; K. Hoekman; C.W. Burger; R.H.M. Verheijen; M. 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 148 KB

CA-125 changes can predict optimal inter

✍ N. Rodriguez; J. Rauh-Hain; C. Feltmate; M. Del Carmen; R. Penson; A. Goodman; U 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 108 KB